Vitrivax Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 52

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $87M

  • Investors
  • 15

Vitrivax General Information

Description

Developer of thermostable vaccine formulations designed to eliminate barriers to global vaccination. The company offers a proprietary atomic-layering thermostable antigen and adjuvant technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response, enabling users to incorporate prime doses and additional booster doses in a single-shot administration.

Contact Information

Website
vitrivaxbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5500 Central Avenue
  • Suite 220
  • Boulder, CO 80301
  • United States
+1 (303)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 5500 Central Avenue
  • Suite 220
  • Boulder, CO 80301
  • United States
+1 (303)

Vitrivax Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vitrivax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series C) 19-Nov-2026 $87M Completed Generating Revenue
9. Later Stage VC (Series B) 17-Nov-2025 Completed Generating Revenue
8. Grant 14-Oct-2025 Completed Generating Revenue
7. Grant 28-Apr-2025 Completed Generating Revenue
6. Grant 04-Dec-2024 Completed Generating Revenue
5. Accelerator/Incubator Completed Generating Revenue
4. Grant 06-Dec-2023 Completed Generating Revenue
3. Later Stage VC (Series A) 10-Apr-2023 Completed Generating Revenue
2. Grant 22-May-2020 $240K Completed Generating Revenue
1. University Spin-Out 01-Jan-2014 Completed Generating Revenue
To view Vitrivax’s complete valuation and funding history, request access »

Vitrivax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series B-2
Series A 5,057,582 $0.001000 $1.85 $1.85 1x $1.85 15.25%
To view Vitrivax’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Vitrivax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of thermostable vaccine formulations designed to eliminate barriers to global vaccination. The company offers
Biotechnology
Boulder, CO
52 As of 2026

Alameda, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vitrivax Competitors (1)

One of Vitrivax’s competitors is iQ Biosciences, a Accelerator/Incubator Backed company based in Alameda, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
iQ Biosciences Accelerator/Incubator Backed Alameda, CA
You’re viewing 1 of 1 competitors. Get the full list »

Vitrivax Patents

Vitrivax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026165138-A2 Compositions and methods for reducing agglomeration of microparticles in coating processes Pending 31-Jan-2025
WO-2026165138-A3 Compositions and methods for reducing agglomeration of microparticles in coating processes Pending 31-Jan-2025
US-20260325460-A1 Compositions, methods and uses for determining atomic layer deposition coating quality and dissolution rates Pending 04-Dec-2023
WO-2025122516-A1 Compositions, methods and uses for determining atomic layer deposition coating quality and dissolution rates Inactive 04-Dec-2023
JP-2026526606-A Composition, method, and use of polynucleotide preparations for drying and long-term storage Pending 28-Jul-2023 A61K9/5123
To view Vitrivax’s complete patent history, request access »

Vitrivax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vitrivax Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eli Lilly Canada Corporation Minority
F-Prime Venture Capital Minority
Nea Venture Capital Minority
Sanofi Ventures Corporate Venture Capital Minority
RA Capital Management Asset Manager Minority
You’re viewing 5 of 15 investors. Get the full list »

Vitrivax FAQs

  • When was Vitrivax founded?

    Vitrivax was founded in 2014.

  • Where is Vitrivax headquartered?

    Vitrivax is headquartered in Boulder, CO.

  • What is the size of Vitrivax?

    Vitrivax has 52 total employees.

  • What industry is Vitrivax in?

    Vitrivax’s primary industry is Biotechnology.

  • Is Vitrivax a private or public company?

    Vitrivax is a Private company.

  • What is Vitrivax’s current revenue?

    The current revenue for Vitrivax is .

  • How much funding has Vitrivax raised over time?

    Vitrivax has raised $125M.

  • Who are Vitrivax’s investors?

    Eli Lilly Canada, F-Prime, Nea, Sanofi Ventures, and RA Capital Management are 5 of 15 investors who have invested in Vitrivax.

  • Who are Vitrivax’s competitors?

    iQ Biosciences is a competitor of Vitrivax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process